Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications.

Myocardial infarction (MI) causes significant cell loss and damage to myocardium. Cell-based therapies for treatment of MI aim to remuscularize the resultant scar tissue, but the majority of transplanted cells do not survive or integrate with the host tissue. Scaffolds can improve cell retention following construct implantation, but often do little to enhance host-graft integration and/or show limited biodegradation. Fibrin is an ideal biomaterial for cardiac tissue engineering as it is a natural, biodegradable polymer that can induce neovascularization, promote cell attachment, and has tunable mechanical properties. Here we describe a novel, high-density microtemplated fibrin scaffold seeded with a tri-cell mixture of cardiomyocytes, endothelial cells (ECs), and fibroblasts to mimic native cardiac tissue in structure and cellular composition to improve cell retention and promote integration with the host tissue. Scaffolds were designed with uniform architecture of parallel 60 μm microchannels surrounded by an interconnected microporous network of 27-μm-diameter pores and mechanical stiffness comparable to native cardiac tissues (70-90kPa). Scaffold degradation was controlled with the addition of Factor XIII (FXIII) and/or protease inhibitor (aprotinin). Unmodified scaffolds had a fast degradation profile both in vitro (19.9%±3.9% stiffness retention after 10 days) and in vivo. Scaffolds treated with FXIII showed an intermediate degradation profile in vitro (45.8%±5.9%), while scaffolds treated with aprotinin or both FXIII and aprotinin showed significantly slowed degradation in vitro (60.9%±5.2% and 76.4%±7.6%, respectively, p<0.05). Acellular aprotinin scaffold myocardial implants showed decreased collagen deposition after 7 days. Unmodified and aprotinin implants could not be located by 14 days, while 2 of 8 FXIII implants were found, but were significantly degraded. Constructs supported seeded cell survival and organization in vitro, promoting EC-lined lumen structure formation in construct channels and colocalization of viable ECs and cardiomyocytes. In addition, constructs promoted extracellular matrix deposition by seeded cells, as shown by collagen staining within construct channels and by significant increases in construct stiffness over 10 days in vitro (209%±32%, p<0.05). The data suggest our fibrin scaffolds are ideally designed to promote graft cell survival and organization, thus improving chances of promoting construct integration with the host tissue upon implantation.

[1]  K. Bendixen,et al.  Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue , 2009, Proceedings of the National Academy of Sciences.

[2]  C. Murry,et al.  Cell therapy enhances function of remote non-infarcted myocardium. , 2009, Journal of molecular and cellular cardiology.

[3]  J. Takagi,et al.  Subunit B of factor XIII is present in bovine platelets. , 1988, Thrombosis research.

[4]  D. Kohane,et al.  Engineering vascularized skeletal muscle tissue , 2005, Nature Biotechnology.

[5]  S K Young,et al.  Neovascularization of immunoisolation membranes: the effect of membrane architecture and encapsulated tissue. , 1992, Transplantation proceedings.

[6]  Israel Nur,et al.  A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants , 2011, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[7]  Charles E. Murry,et al.  Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture , 2011, Circulation research.

[8]  Steven C George,et al.  Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. , 2009, Tissue engineering. Part A.

[9]  Z. Koncz,et al.  Factor XIII, clot structure, thrombosis. , 2012, Thrombosis research.

[10]  Aldo R Boccaccini,et al.  Myocardial tissue engineering. , 2008, British medical bulletin.

[11]  K. Sueishi,et al.  Effects of fibrin on the angiogenesis in vitro of bovine endothelial cells in collagen gel , 1995, In Vitro Cellular & Developmental Biology - Animal.

[12]  R. C. Johnson,et al.  Neovascularization of synthetic membranes directed by membrane microarchitecture. , 1995, Journal of biomedical materials research.

[13]  Amber N. Stratman,et al.  Mechanisms controlling human endothelial lumen formation and tube assembly in three-dimensional extracellular matrices. , 2007, Birth defects research. Part C, Embryo today : reviews.

[14]  Lil Pabon,et al.  Scaffold-free human cardiac tissue patch created from embryonic stem cells. , 2009, Tissue engineering. Part A.

[15]  S. Reeves,et al.  Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action , 2007, Anesthesia and analgesia.

[16]  Tadashi Sasagawa,et al.  Design of prevascularized three-dimensional cell-dense tissues using a cell sheet stacking manipulation technology. , 2010, Biomaterials.

[17]  N. Kipshidze,et al.  Transplantation of Autologous Endothelial Cells Induces Angiogenesis , 2003, Pacing and clinical electrophysiology : PACE.

[18]  Michael Regnier,et al.  Investigation of thin filament near‐neighbour regulatory unit interactions during force development in skinned cardiac and skeletal muscle , 2007, The Journal of physiology.

[19]  Seung‐Woo Cho,et al.  Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. , 2005, Biomaterials.

[20]  Yen-Chih Huang,et al.  Contractile three-dimensional bioengineered heart muscle for myocardial regeneration. , 2007, Journal of biomedical materials research. Part A.

[21]  Randall J Lee,et al.  Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. , 2004, Tissue engineering.

[22]  Michael Regnier,et al.  Substrate stiffness increases twitch power of neonatal cardiomyocytes in correlation with changes in myofibril structure and intracellular calcium. , 2011, Biophysical journal.

[23]  O. Fichet,et al.  Fibrin-polyethylene oxide interpenetrating polymer networks: new self-supported biomaterials combining the properties of both protein gel and synthetic polymer. , 2011, Acta Biomaterialia.

[24]  S. Cook,et al.  Hydrogel-based engineered skeletal muscle grafts normalize heart function early after myocardial infarction. , 2008, Artificial organs.

[25]  Jennifer R. Hurley,et al.  Complex temporal regulation of capillary morphogenesis by fibroblasts. , 2010, American journal of physiology. Cell physiology.

[26]  Dougald M Monroe,et al.  What does it take to make the perfect clot? , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Buddy D Ratner,et al.  Degradable, thermo-sensitive poly(N-isopropyl acrylamide)-based scaffolds with controlled porosity for tissue engineering applications. , 2010, Biomacromolecules.

[28]  Buddy D. Ratner,et al.  A fibrinogen-based precision microporous scaffold for tissue engineering. , 2007, Biomaterials.

[29]  M. Hincke,et al.  Fibrin: a versatile scaffold for tissue engineering applications. , 2008, Tissue engineering. Part B, Reviews.

[30]  A. Balbarini,et al.  Fibrin as a scaffold for cardiac tissue engineering , 2011, Biotechnology and applied biochemistry.

[31]  Lei Yuan,et al.  Engineering Robust and Functional Vascular Networks In Vivo With Human Adult and Cord Blood–Derived Progenitor Cells , 2008, Circulation research.

[32]  D. Bull,et al.  Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. , 2003, The Annals of thoracic surgery.

[33]  Shulamit Levenberg,et al.  Tissue Engineering of Vascularized Cardiac Muscle From Human Embryonic Stem Cells , 2007, Circulation research.

[34]  C. Murry,et al.  Systems approaches to preventing transplanted cell death in cardiac repair. , 2008, Journal of molecular and cellular cardiology.

[35]  Lauran R. Madden,et al.  Proangiogenic scaffolds as functional templates for cardiac tissue engineering , 2010, Proceedings of the National Academy of Sciences.

[36]  J. Weisel,et al.  Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. , 2007, Blood.

[37]  S. Levenberg,et al.  Vascularization : The Conduit to Viable Engineered Tissues , 2010 .